Mesoblast limited (NASDAQ:MESO) Expected to Announce Earnings of -$0.24 Per Share

Wall Street analysts forecast that Mesoblast limited (NASDAQ:MESO) will announce earnings of ($0.24) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Mesoblast’s earnings, with the lowest EPS estimate coming in at ($0.25) and the highest estimate coming in at ($0.22). Mesoblast reported earnings of ($0.22) per share in the same quarter last year, which would suggest a negative year over year growth rate of 9.1%. The business is expected to issue its next earnings results on Wednesday, September 4th.

According to Zacks, analysts expect that Mesoblast will report full-year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($1.00) to ($0.82). For the next financial year, analysts anticipate that the firm will post earnings of ($0.97) per share, with EPS estimates ranging from ($1.08) to ($0.85). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Mesoblast.

Mesoblast (NASDAQ:MESO) last released its earnings results on Thursday, May 30th. The company reported ($0.25) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.25). The company had revenue of $1.25 million for the quarter, compared to analyst estimates of $1.23 million. Mesoblast had a negative net margin of 546.34% and a negative return on equity of 17.13%.

Several brokerages have weighed in on MESO. Chardan Capital set a $6.00 price target on shares of Mesoblast and gave the company a “hold” rating in a research report on Friday, May 31st. ValuEngine cut shares of Yirendai from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 26th. Zacks Investment Research cut shares of Home Bancshares from a “hold” rating to a “sell” rating in a research report on Friday, June 7th. HC Wainwright reaffirmed a “buy” rating on shares of Zomedica Pharmaceuticals in a research report on Wednesday, June 5th. Finally, Maxim Group set a $3.00 price objective on shares of Biopharmx and gave the company a “buy” rating in a research note on Wednesday, June 12th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Mesoblast presently has an average rating of “Buy” and an average price target of $12.13.

An institutional investor recently bought a new position in Mesoblast stock. OLD Mission Capital LLC purchased a new position in Mesoblast limited (NASDAQ:MESO) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 14,547 shares of the company’s stock, valued at approximately $60,000. Hedge funds and other institutional investors own 2.76% of the company’s stock.

MESO traded up $0.01 during trading on Friday, hitting $5.25. 10,778 shares of the stock traded hands, compared to its average volume of 79,524. The company has a market cap of $494.40 million, a price-to-earnings ratio of -8.33 and a beta of 1.86. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.92 and a quick ratio of 1.92. The company has a 50-day moving average price of $5.09. Mesoblast has a 12-month low of $3.35 and a 12-month high of $8.78.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Featured Article: What is the QQQ ETF?

Get a free copy of the Zacks research report on Mesoblast (MESO)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with's FREE daily email newsletter.